Tempest Therapeutics, Inc. SEC filings TPST
Tempest Therapeutics, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Feb 1, 2013. Its latest annual report, Form ARS, was filed on Nov 2, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 3 | Initial insider ownership | Nov 3, 2026 | Oct 26, 2026 |
| 4 | Insider transaction | Nov 2, 2026 | Oct 13, 2026 |
| 3 | Initial insider ownership | Nov 2, 2026 | Oct 13, 2026 |
| ARS | Annual report to shareholders | Nov 2, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 30, 2026 | Oct 26, 2026 |
| DEF 14A | Proxy statement | Oct 26, 2026 | Nov 9, 2026 |
| DEFA14A | Additional proxy material | Oct 20, 2026 | — |
| 8-K |
Current report
Shareholder vote results, Other events
|
Oct 20, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 19, 2026 | Oct 13, 2026 |
| PRE 14A | Preliminary proxy statement | Oct 16, 2026 | Nov 9, 2026 |
| D | Filing | Oct 14, 2026 | — |
| 4 | Insider transaction | Oct 2, 2026 | Sep 22, 2026 |
| 3 | Initial insider ownership | Oct 2, 2026 | Sep 22, 2026 |
| 424B3 | Prospectus | Oct 2, 2026 | — |
| EFFECT | Filing | Oct 1, 2026 | — |
| 8-K |
Current report
Material agreement, Officer or director change, Regulation FD disclosure
|
Sep 28, 2026 | Sep 22, 2026 |
| S-3 | Shelf registration | Sep 25, 2026 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 17, 2026 | Sep 14, 2026 |
| DEFA14A | Additional proxy material | Sep 16, 2026 | — |
| 8-K |
Current report
Shareholder vote results, Other events
|
Sep 16, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 15, 2026 | Sep 11, 2026 |
| 424B3 | Prospectus | Sep 1, 2026 | — |
| EFFECT | Filing | Aug 31, 2026 | — |
| CORRESP | Letter to the SEC | Aug 27, 2026 | — |
| UPLOAD | Letter from the SEC | Aug 27, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Aug 24, 2026 | Aug 18, 2026 |
| S-1 | Registration statement | Aug 21, 2026 | — |
| DEFA14A | Additional proxy material | Aug 18, 2026 | — |
| 8-K |
Current report
Shareholder vote results, Other events
|
Aug 18, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 13, 2026 | Aug 13, 2026 |
| DEFA14A | Additional proxy material | Jul 28, 2026 | — |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jul 28, 2026 | Jul 27, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 22, 2026 | Jul 17, 2026 |
| DEF 14A | Proxy statement | Jul 17, 2026 | Jul 27, 2026 |
| 424B3 | Prospectus | Jul 8, 2026 | — |
| EFFECT | Filing | Jul 7, 2026 | — |
| PRE 14A | Preliminary proxy statement | Jul 7, 2026 | Jul 27, 2026 |
| CORRESP | Letter to the SEC | Jul 2, 2026 | — |
| UPLOAD | Letter from the SEC | Jul 2, 2026 | — |
| S-3 | Shelf registration | Jun 26, 2026 | — |
| 4 | Insider transaction | Jun 23, 2026 | Mar 24, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 18, 2026 |
| D | Filing | Jun 23, 2026 | — |
| 4 | Insider transaction | Jun 17, 2026 | Jun 4, 2026 |
| 3 | Initial insider ownership | Jun 17, 2026 | Jun 4, 2026 |
| 3 | Initial insider ownership | Jun 8, 2026 | Jun 4, 2026 |
| 4 | Insider transaction | Jun 8, 2026 | Jun 4, 2026 |
| DEF 14A | Proxy statement | Jun 8, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 4, 2026 | May 29, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jun 2, 2026 | May 28, 2026 |
| PRE 14A | Preliminary proxy statement | May 29, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Officer or director change
|
May 29, 2026 | May 23, 2026 |
| 8-K |
Current report
Listing notice
|
May 22, 2026 | May 19, 2026 |
| 8-K |
Current report
Officer or director change
|
May 22, 2026 | May 22, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 6, 2026 | May 6, 2026 |
| 424B3 | Prospectus | Apr 10, 2026 | — |
| 424B3 | Prospectus | Apr 10, 2026 | — |
| EFFECT | Filing | Apr 9, 2026 | — |
| CORRESP | Letter to the SEC | Apr 8, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2026 | — |
| EFFECT | Filing | Apr 3, 2026 | — |
| D | Filing | Apr 3, 2026 | — |
| 4 | Insider transaction | Apr 2, 2026 | Mar 31, 2026 |
| 4 | Insider transaction | Apr 2, 2026 | Mar 31, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Apr 2, 2026 | — |
| S-3 | Shelf registration | Apr 2, 2026 | — |
| CORRESP | Letter to the SEC | Apr 1, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2026 | — |
| S-8 POS | Filing | Mar 31, 2026 | — |
| S-3 | Shelf registration | Mar 30, 2026 | — |
| S-8 | Employee stock plan registration | Mar 30, 2026 | — |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 30, 2026 | Mar 30, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 25, 2026 | — |
| 4 | Insider transaction | Mar 25, 2026 | Mar 24, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Mar 23, 2026 | Mar 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 25, 2026 | Feb 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 11, 2026 | Feb 11, 2026 |
| SCHEDULE 13D | Ownership over 5% (active) | Feb 10, 2026 | — |
| 4 | Insider transaction | Feb 6, 2026 | Feb 4, 2026 |
| 3 | Initial insider ownership | Feb 6, 2026 | Feb 3, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change in control, Officer or director change
|
Feb 6, 2026 | Feb 3, 2026 |
| 4 | Insider transaction | Jan 28, 2026 | Jan 27, 2026 |
| 4 | Insider transaction | Jan 28, 2026 | Jan 27, 2026 |
| 4 | Insider transaction | Jan 28, 2026 | Jan 27, 2026 |
| 4 | Insider transaction | Jan 28, 2026 | Jan 27, 2026 |
| 8-K |
Current report
Change to shareholder rights, Officer or director change, Shareholder vote results
|
Jan 28, 2026 | Jan 27, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 21, 2026 | — |
| 8-K |
Current report
Listing notice
|
Jan 9, 2026 | Jan 8, 2026 |
| EFFECT | Filing | Dec 31, 2025 | — |
| ARS | Annual report to shareholders | Dec 31, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Dec 31, 2025 | Jan 27, 2026 |
| CORRESP | Letter to the SEC | Dec 30, 2025 | — |
| CORRESP | Letter to the SEC | Dec 23, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2025 | — |
| S-1 | Registration statement | Dec 9, 2025 | — |
| PRE 14A | Preliminary proxy statement | Dec 2, 2025 | Dec 31, 2025 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Nov 26, 2025 | Nov 24, 2025 |
| 424B5 | Prospectus supplement | Nov 25, 2025 | — |
| DEFA14A | Additional proxy material | Nov 19, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Other events
|
Nov 19, 2025 | Nov 19, 2025 |
| 10-Q | Quarterly report | Nov 5, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2025 | Nov 5, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Aug 13, 2025 | — |
| 10-Q | Quarterly report | Aug 11, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Jun 12, 2025 | Jun 11, 2025 |
| 424B5 | Prospectus supplement | Jun 12, 2025 | — |
| 8-K |
Current report
Other events
|
Jun 11, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Officer or director change
|
Jun 6, 2025 | Jun 5, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| 10-K/A | Amended annual report | Apr 30, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Other events
|
Apr 28, 2025 | Apr 24, 2025 |
| 8-K |
Current report
Exit or restructuring costs
|
Apr 18, 2025 | Apr 17, 2025 |
| 8-K |
Current report
Agreement ended, Regulation FD disclosure
|
Apr 9, 2025 | Apr 8, 2025 |
| 8-K |
Current report
Change to shareholder rights
|
Apr 7, 2025 | Apr 4, 2025 |
| S-8 | Employee stock plan registration | Mar 27, 2025 | — |
| 10-K | Annual report | Mar 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2025 | Mar 27, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Feb 11, 2025 | — |
| 424B5 | Prospectus supplement | Feb 6, 2025 | — |
| EFFECT | Filing | Jan 27, 2025 | — |
| CORRESP | Letter to the SEC | Jan 24, 2025 | — |
| S-3/A | Filing | Jan 24, 2025 | — |
| 4 | Insider transaction | Jan 6, 2025 | Jan 2, 2025 |
| 4 | Insider transaction | Jan 6, 2025 | Jan 2, 2025 |
| 4 | Insider transaction | Jan 6, 2025 | Jan 2, 2025 |
| 4 | Insider transaction | Jan 6, 2025 | Jan 2, 2025 |
| 8-K |
Current report
Listing notice
|
Dec 31, 2024 | Dec 27, 2024 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Shareholder vote results
|
Dec 6, 2024 | Dec 3, 2024 |
| DEF 14A | Proxy statement | Nov 12, 2024 | Dec 3, 2024 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| PRE 14A | Preliminary proxy statement | Oct 29, 2024 | Dec 3, 2024 |
| 8-A12B/A | Filing | Oct 10, 2024 | — |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Other events
|
Oct 10, 2024 | Oct 7, 2024 |
| 144 | Notice of proposed sale | Aug 13, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Aug 12, 2024 | — |
| 4 | Insider transaction | Aug 12, 2024 | Aug 8, 2024 |
| 144 | Notice of proposed sale | Aug 9, 2024 | — |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| UPLOAD | Letter from the SEC | Jul 23, 2024 | — |
| S-3 | Shelf registration | Jul 19, 2024 | — |
| 4 | Insider transaction | Jul 8, 2024 | Jul 3, 2024 |
| 4 | Insider transaction | Jul 3, 2024 | Jul 2, 2024 |
| 4 | Insider transaction | Jul 2, 2024 | Jun 28, 2024 |
| 424B5 | Prospectus supplement | Jun 20, 2024 | — |
| 8-K |
Current report
Material agreement, Other events
|
Jun 20, 2024 | Jun 20, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 13, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 13, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 13, 2024 |
| 4 | Insider transaction | Jun 14, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2024 | Jun 13, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | May 13, 2024 | — |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| ARS | Annual report to shareholders | Apr 23, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 23, 2024 | — |
| DEF 14A | Proxy statement | Apr 23, 2024 | Jun 13, 2024 |
| S-8 | Employee stock plan registration | Mar 19, 2024 | — |
| 10-K | Annual report | Mar 19, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 19, 2024 | Mar 19, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 9, 2024 | — |
| SC 13D/A | Amended ownership over 5% (active) | Feb 8, 2024 | — |
| 4 | Insider transaction | Jan 5, 2024 | Jan 3, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 3, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 3, 2024 |
| 4 | Insider transaction | Jan 5, 2024 | Jan 3, 2024 |
| S-8 POS | Filing | Nov 17, 2023 | — |
| S-8 POS | Filing | Nov 17, 2023 | — |
| S-8 POS | Filing | Nov 17, 2023 | — |
| S-8 POS | Filing | Nov 17, 2023 | — |
| S-8 POS | Filing | Nov 17, 2023 | — |
| S-8 | Employee stock plan registration | Nov 17, 2023 | — |
| SC 13D/A | Amended ownership over 5% (active) | Nov 9, 2023 | — |
| 10-Q | Quarterly report | Nov 8, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2023 | Nov 8, 2023 |
| 144 | Notice of proposed sale | Nov 2, 2023 | — |
| 8-K |
Current report
Other events
|
Oct 30, 2023 | Oct 26, 2023 |
| 4 | Insider transaction | Oct 13, 2023 | Oct 11, 2023 |
| 4 | Insider transaction | Oct 13, 2023 | Oct 11, 2023 |
| 4 | Insider transaction | Oct 13, 2023 | Oct 11, 2023 |
| 4 | Insider transaction | Oct 13, 2023 | Oct 11, 2023 |
| 424B5 | Prospectus supplement | Oct 12, 2023 | — |
| 8-A12B | Filing | Oct 11, 2023 | — |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Oct 11, 2023 | Oct 10, 2023 |
| 8-K |
Current report
Listing notice
|
Sep 8, 2023 | Sep 6, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 7, 2023 | Sep 2, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 4 | Insider transaction | Jun 20, 2023 | Jun 15, 2023 |
| 4 | Insider transaction | Jun 20, 2023 | Jun 15, 2023 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TPST (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1544227
- Former names
- Millendo Therapeutics, Inc. (until Jul 1, 2021); OvaScience, Inc. (until Dec 6, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.